Mezzopram Dispersible gastro-resistant tablets are indicated in: Adults • Treatment of duodenal ulcers • Prevention of relapse of duodenal ulcers • Treatment of gastric ulcers • Prevention of relapse of gastric ulcers • In combination with appropriate antibiotics, Helicobacter pylori (H. pylori) eradication in peptic ulcer disease • Treatment of NSAID-associated gastric and duodenal ulcers • Prevention of NSAID-associated gastric and duodenal ulcers in patients at risk • Treatment of reflux oesophagitis • Long-term management of patients with healed reflux oesophagitis • Treatment of symptomatic gastro-oesophageal reflux disease • Treatment of Zollinger-Ellison syndrome Children Children over 1 year of age and ≥ 10 kg • Treatment of reflux oesophagitis • Symptomatic treatment of heartburn and acid regurgitation in gastro-oesophageal reflux disease Children over 4 years of age and adolescents • In combination with antibiotics in treatment of duodenal ulcer caused by H. pylori
Refractory seizures associated with tuberous sclerosis complex (TSC) Votubia is indicated as adjunctive treatment of patients aged 2 years and older whose refractory partial onset seizures, with or without secondary generalisation, are associated with TSC. Subependymal giant cell astrocytoma (SEGA) associated with TSC Votubia is indicated for the treatment of adult and paediatric patients with SEGA associated with TSC who require therapeutic intervention but are not amenable to surgery. The evidence is based on analysis of change in SEGA volume. Further clinical benefit, such as improvement in disease-related symptoms, has not been demonstrated.